Gyncentrum Sp. z o.o.
- Address
- lock Available on a paid plan
Immune System Diseases
The dermatology unit at Gyncentrum Sp. z o.o. is investigating immune‑mediated skin disorders, with a focus on Atopic Dermatitis and the potential of novel biologic agents to improve patient outcomes.
- Evaluation of rocatinlimab in combination with topical therapies
- Placebo‑controlled, double‑blind efficacy assessment
- Use of the Validated Investigator’s Global Assessment to measure disease improvement
With 15 investigators contributing, the site aims to expand therapeutic options for immune‑driven skin conditions while maintaining a patient‑focused approach.
Nervous System Diseases
Research at this clinic also addresses neuropathic itch, specifically moderate‑to‑severe pruritus linked to Notalgia Paresthetica, by testing oral agents that target nerve‑related pathways.
- Dose‑finding study of difelikefalin versus placebo
- Measurement of itch intensity reduction after eight weeks of treatment
- Assessment of safety and tolerability in adult participants
These trials contribute to a better understanding of how nervous system dysfunction drives chronic itching and explore new avenues for relief.
Skin and Connective Tissue Diseases
The department’s broader dermatology program evaluates both disease severity and therapeutic synergy in conditions such as Atopic Dermatitis, integrating systemic and topical approaches.
- Monitoring disease activity with the Eczema Area and Severity Index (EASI)
- Combining topical corticosteroids and calcineurin inhibitors with investigational agents
- Tracking clinical outcomes in moderate‑to‑severe patients
Located in Katowice, Poland, the non‑commercial site leverages its expertise to advance care for skin and connective tissue disorders across Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 12 therapeutic areas and 15 of 30 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Probelte Pharma S.L.2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Probelte Pharma S.L.2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gyncentrum Sp. z o.o.
lock Showing 1 of 23 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis | Inmagene LLC | Phase II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 30 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Allergenic Extract Of Grass Pollen Mixture: Dactylis Glomerata, Festuca Pratensis, Lolium Perenne, Phleum Pratense And Poa Pratensis (1:1:1:1:1), Polymerised | 2 | Unknown | — | — |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.